Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

HK Type 4 license through Ballingal Investment Advisors Ltd. 

I'm a highly experienced sell-side analyst with in excess of 22 years of covering Asia Pacific equities, the past 19 years immersed in event strategies encompassing M&A risk arbitrage, directional long/short, stub trades and restructuring.  

My background also includes accountancy (liquidation/bankruptcy/receivership) earlier in my career and as a chief financial officer of a global commodity company based in the US and Mexico.

Pan-Asia Catalysts/Events

Estia Health: Bain's Non-Binding Proposal

Quiddity Advisors

Event-Driven

<ul>
<li>After its initial bid of $3.00/share was rejected by <strong><a href="https://www.smartkarma.com/entities/estia-health-ltd" target="_blank" data-smartkarma-citation="entities:77:1" rel="noopener">Estia Health (EHE AU)</a></strong>, Bain returned on the 7 June with a $3.20/share non-binding proposal and was granted exclusive due diligence.</li>
<li>Estia and Bain Capital have now entered into a Scheme Implementation Agreement at A$3.20/share, a 50% premium to undisturbed. </li>
<li>A shareholder meeting is expected to be held in November with implementation expected prior to the end of 2023. </li>
</ul>


After its initial bid of $3.00/share was rejected by Estia Health (EHE AU), Bain returned on the 7 June with a $3.20/share non-binding proposal and was granted exclusive due diligence.
Estia and Bain Capital have now entered into a Scheme Implementation Agreement at A$3.20/share, a 50% premium to undisturbed. 
A shareholder meeting is expected to be held in November with implementation expected prior to the end of 2023. 


Estia Health

Estia & Bain Enter Into Scheme Agreement